OGT further expands global direct sales and support into Asia-Pacific region
Oxford, UK –Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it has expanded its direct sales of Cytocell Fluorescence In Situ Hybridisation (FISH) products to include the Asia-Pacific (APAC) region. OGT will provide customers inSingapore, Malaysia, Vietnam, Australia, and New Zealand with enhanced local sales and support services via established affiliates of Sysmex Corporation, as well as via continued collaboration with existing distributors. The move follows the successful introduction of selling via a number of European Sysmex affiliates earlier this year.
OGT’s Cytocell brand is well-known for providing the widest range of high-quality, reliable, and cost-effective FISH probes on the market, as well as excellent customer support, service, and expertise. To grow and maintain its renowned exceptional customer support services on a global scale, OGT is also delivering extensive training programmes across the portfolio for Sysmex staff in EMEA and APAC.
In addition to the expansion into APAC, OGT is increasing its global logistics cooperation with Sysmex, providing customers with extra levels of support and convenience. The company has recently opened a new Cytocell customer service and distribution centre, initially for customers in the USA, located in Lincolnshire, IL, at the Sysmex America, Inc. (SAI) Headquarters. By working closely with SAI, OGT will be able to deliver extended ordering and shipping hours, and plans to establish a Singapore distribution centre to serve customers in APAC in the future.
Spencer Howell, Executive VP Sales at OGT, remarked, “Building on the successes of previous initiatives to establish direct sales through Sysmex affiliates, which have provided many benefits to customers in Poland, Czechia, Slovakia, France, Belgium, Switzerland and Luxembourg, we are now focusing on APAC where we see enormous growth potential. With increased local support and activity, backed by larger Sysmex affiliate organisations, we will increase our visibility, deliver growth, and be able to better realise the opportunities. The expanding cooperation with Sysmex delivers the benefits of being part of a larger organisation to our customers, providing them with enhanced local service and support, something we are committed to continue developing”.
For more information please visit www.cytocell.com/contact.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitro diagnostic company in June 2017. The acquisition of OGT expands Sysmex’s life science business and reinforces its initiatives towards personalised medicine.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. Cytocell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemisation and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimise individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 8,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.